AREVA Group Chooses Caen (France) as the Location for Its Second Lead-212 Production Facility
Luc Oursel, President of AREVA, announced the selection of the Caen la Mer urban community (Calvados, France) as the location for its second lead-212 production facility.
The future production facility of AREVA Med, the subsidiary dedicated to the development of cancer treatments, will provide an industrial production capacity to complement the Maurice Tubiana Facility in Bessines (Haute-Vienne, France). Based in the Basse-Normandie region, the construction of this facility will be confirmed following important scientific programs underway. Lead-212 is a rare metal used in the development of targeted and innovative treatments for certain cancers that do not respond to other conventional methods. The first commercial production is planned for 2020.
For more information visit: www.areva.com